Download PDF
Thromb Haemost 1988; 59(02): 216-220
DOI: 10.1055/s-0038-1642757
Original Articles
Schattauer GmbH Stuttgart

A Randomized Double-Blind Study Between a Low Molecular Weight Heparin Kabi 2165 and Standard Heparin in the Prevention of Deep Vein Thrombosis in General Surgery

A French Multicenter Trial
J P Caen
The Unité 150 INSERM, Hôspital Lariboisiére, Paris, France
› Author Affiliations
Further Information

Publication History

Received 14 September 1987

Accepted after revision 26 November 1987

Publication Date:
31 May 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The safety and efficacy of a low molecular weight heparin fragment Kabi 2165, given in the dose 2,500 anti-Xa units once daily, in preventing postoperative venous thromboembolism, was assessed against calcium heparin in the dose 5,000 IU twice daily, in a multicenter double blind randomized study. On an intention to treat basis 385 patients scheduled for major surgery were included in this study. Six patients (3.1%) out of 195 developed isotopic DVT in the Kabi 2165 group. Corresponding figures for calcium heparin was 7 patients (3.7%). There was no statistically significant difference between the two groups with respect to the bleeding variables; blood loss during operation, postoperative drainage, blood transfusion, haemoglobin and haematocrit levels; wound haematoma and haematoma at the injection sites. No patient had to undergo evacuation of wound haematoma or reoperation due to bleeding. It is concluded that one single daily injection of Kabi 2165 provides a convenient safe and effective prophylaxis against thromboembolism in general surgery.

Keywords

Low molecular weight heparin - Deep vein thromboisis - Bleeding anti-Xa activity
 

  • References

  • 1 International Multicenter Trial. Preventive of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975; II: 45-51
    PubMedGoogle Scholar
  • 2 Kiil J, Akelsen F, Andersen D. Prophylaxis against postoperative pulmonary embolism and deep vein thrombosis by low dose heparin. Lancet 1986; I: 1115-1116
    PubMedGoogle Scholar
  • 3 Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Soderstrom G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralisation in plasma. Thromb Res 1979; 15: 531-541
    CrossrefPubMedGoogle Scholar
  • 4 Holmer E, Soderberg K, Bergqvist D, Lindahl U. Heparin and its low molecular weight derivatives. Anticoagulant and antithrombotic properties. Haemostasis 1986; 16 suppl (Suppl. 02) 1-7
    PubMedGoogle Scholar
  • 5 Bergqvist D, Hedner U, Sjorin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983; 32: 381-391
    CrossrefPubMedGoogle Scholar
  • 6 Kakkar VV, Nicolaides AN, Renney J, Friend JR, Clarke MD. 125I- fibrinogen test adopted for routine screening. Lancet 1970; I: 540-542
    PubMedGoogle Scholar
  • 7 Prevention of Deep Venous Thrombosis and Pulmonary Embolism. Lancet 1978; I: 1202-1203
    PubMed
  • 8 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
    CrossrefPubMedGoogle Scholar
  • 9 Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low molecular weight heparin and prevention of postoperative deep vein thrombosis. Brit Med J 1982; 284: 375-379
    CrossrefPubMedGoogle Scholar
  • 10 Kakkar VV, Murray WJ G. Efficacy and safety low molecular weight heparin (CY 216) in preventing postoperative venous thromboembolism: a co-operative study. Br J Surg 1985; 72: 786-791
    CrossrefPubMedGoogle Scholar
  • 11 Kakkar VV, Kakkar S, Sanderson RM, Peers CE. Efficacy and safety of two regimens of low molecular weight heparin fragment (fragmin) in preventing postoperative venous thrombolism. Haemostasis 1986; 16 suppl (Suppl. 02) 19-24
    PubMedGoogle Scholar
  • 12 Schmitz-Huebner U, Brente H, Freise G, Reers B. et al Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wchs Chir 1984; 62: 344-353
    PubMedGoogle Scholar
  • 13 Koller M, Schoch U, Buchmann P, Largiader F, von Felten A, Frick PB. Thrombosis prophylaxis in visceral surgery with the low molecular weight heparin fragment Kabi 2165 (7500 and 2500 anti-Xa U/day). Haemostasis 1986; 16 suppl (Suppl. 02) 19-24
    PubMedGoogle Scholar
  • 14 Bergqvist D, Burmark US, Frisell J, Mallbook T. et al Prospective double blind comparison between Fragmin and conventional low dose heparin: thromboprophylactic effect and bleeding complications. Haemostasis 1986; 16 suppl (Suppl. 02) 11-18
    PubMedGoogle Scholar
  • 15 Turpie AG G, Levine MN, Hirsh J. et al A randomized controlled trial of PK 10169 low molecular weight heparin in the prevention of deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929
    CrossrefPubMedGoogle Scholar
  • 16 Turpie AG G, Levine MN, Hirsh J. et al A double blind randomized trial of ORG 10172 low molecular weight heparinoid in the prevention of deep vein thrombosis in patients with thrombotic stroke. Lancet 1987; 1: 523-526
    PubMedGoogle Scholar
  • 17 ten Cate H, Henny P, ten Cate JW, Biiller HR, Dabhoiwala NF. Randomized double blind placebo controlled safety study of a low molecular weight heparinoid in patients undergoing transurethral resection of the prostate. Thromb Haemostas 1987; 57: 92-96
    PubMedGoogle Scholar